Skip to Content
  • Previous Rank-
  • Revenue 3 Yr Annual Growth Rate18%
  • Revenue 3 Yr Growth Rank83
  • EPS 3 Yr Annual Growth Rate28%
  • EPS 3 Yr Growth Rank71
  • Total Return 3 Yr Annual Rate66%
  • Total Return 3 Yr Rank
    6

Demand in China far exceeds supply for this biopharma company’s blood products, which it derives from human plasma.

Fortune Data StoreLooking for leads, investment insights, or competitive intelligence?Get Premium Access

Company Information

Location
Beijing, China
Industry
Pharmaceuticals
Sector
Health Care
Current Streak-
Years on List1
CEO
David Xiaoying Gao
Websitehttp://www.chinabiologic.com
Incorporated in the United States.!Revenue and net income for the four quarters ended on or before April 30, 2016.!Total return for the period ended June 30, 2016.

Revenue, Net Income

Revenue Past Four Quarters ($M)$312
Net Income Past Four Quarters ($M)$92

Growth Rates and Ranks

Revenue 3 Yr Growth Rank83
EPS 3 Yr Annual Growth Rate28%
EPS 3 Yr Growth Rank71
Total Return 3 Yr Annual Rate66%
Total Return 3 Yr Rank
6